sirolimus kaposi's sarcoma renal-transplant recipients pubmed ncbi abstract background recipients organ transplants susceptible kaposi's sarcoma result treatment immunosuppressive drugs sirolimus rapamycin immunosuppressive drug antitumor effects methods stopped cyclosporine therapy num kidney-transplant recipients biopsy-proven kaposi's sarcoma began sirolimus therapy patients underwent excisional biopsy lesion biopsy normal skin time diagnosis biopsy performed site previous kaposi's sarcoma lesion months sirolimus therapy begun examined biopsy specimens vascular endothelial growth factor vegf flk num kdr protein phosphorylated akt num kinase enzymes signaling pathway targeted sirolimus results months sirolimus therapy begun cutaneous kaposi's sarcoma lesions disappeared patients remission confirmed histologically patients months sirolimus therapy begun acute episodes rejection kidney-graft function levels flk num kdr phosphorylated akt num kinase increased kaposi's sarcoma cells expression vegf increased kaposi's sarcoma cells normal skin cells kaposi's sarcoma lesions conclusions sirolimus inhibits progression dermal kaposi's sarcoma kidney-transplant recipients providing effective immunosuppression copyright num massachusetts medical society 
